Literature DB >> 9379059

CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus.

S Blossom1, E B Chu, W O Weigle, K M Gilbert.   

Abstract

Male BXSB mice, unlike female BXSB, develop a severe early onset lupus-like disease that has been linked to an intrinsic B cell defect. In investigating this B cell defect the present study showed that male, but not female, BXSB contained a higher percentage of large, activated splenic B cells that were more responsive to anti-CD40 mAb-induced proliferation. The hyperactivity of the large B cells from the male mice was also observed in the absence of anti-CD40 mAb or any other stimuli. In examining the mechanism of the B cell hyperactivity, it was found that 20% of unstimulated large B cells from male mice, unlike large B cells from female mice, expressed CD40 ligand (CD40L), a molecule normally expressed on activated CD4+ cells. The percentage of large B cells from the male BXSB that expressed CD40L was increased to 43% by stimulation with LPS. A functional role for CD40L expression on B cells was confirmed by showing that CD40-Ig blocked the spontaneous proliferation of the large B cells from male mice. In addition, the stimulatory capacity of the large B cells from the male mice was demonstrated by their ability to induce DNA synthesis in small B cells in a CD40L-dependent manner. These results demonstrated that large B cells from male BXSB expressed functionally active CD40L. It is likely that the B cell CD40L expression and increased susceptibility to CD40 signaling due to an intrinsic B cell hyperactivity promotes autoimmune disease in BXSB mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Life and death within germinal centres: a double-edged sword.

Authors:  Liliana Guzman-Rojas; Jennifer C Sims-Mourtada; Roberto Rangel; Hector Martinez-Valdez
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

2.  Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas.

Authors:  Anna Bolduc; Eugene Long; Dale Stapler; Marilia Cascalho; Takeshi Tsubata; Pandelakis A Koni; Michiko Shimoda
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

3.  Antibody production in autoimmune BXSB mice. I. CD40L-expressing B cells need fewer signals for polyclonal antibody synthesis.

Authors:  S Blossom; K M Gilbert
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 4.  When the balance is broken: X-linked gene dosage from two X chromosomes and female-biased autoimmunity.

Authors:  Camille M Syrett; Montserrat C Anguera
Journal:  J Leukoc Biol       Date:  2019-05-24       Impact factor: 4.962

Review 5.  New therapies for systemic lupus erythematosus.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 6.  T cells as a therapeutic target in SLE.

Authors:  D Comte; M P Karampetsou; G C Tsokos
Journal:  Lupus       Date:  2015-04       Impact factor: 2.911

Review 7.  T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules.

Authors:  M J Yellin; U Thienel
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 8.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

Review 9.  Targeting Toll-like receptors for treatment of SLE.

Authors:  Christopher G Horton; Zi-jian Pan; A Darise Farris
Journal:  Mediators Inflamm       Date:  2010-09-19       Impact factor: 4.711

10.  Aberrant CD40-induced NF-κB activation in human lupus B lymphocytes.

Authors:  Wen Zhang; Qun Shi; Xiaotian Xu; Hua Chen; Wei Lin; Fengchun Zhang; Xiaofeng Zeng; Xuan Zhang; Denian Ba; Wei He
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.